World Health Organization. Antimicrobial resistance.https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

Jabbari Shiadeh SM, Pormohammad A, Hashemi A, Lak P (2019) Global prevalence of antibiotic resistance in blood-isolated Enterococcus faecalis and Enterococcus faecium: a systematic review and meta-analysis. Infect Drug Resist 12:2713–2725. https://doi.org/10.2147/IDR.S206084

Article  PubMed  PubMed Central  Google Scholar 

Monticelli J, Di Bella S, Giacobbe DR et al (2021) Trends in the incidence and antibiotic resistance of enterococcal bloodstream isolates: a 7-year retrospective multicenter epidemiological study in Italy. Microb Drug Resist 27:529–535. https://doi.org/10.1089/mdr.2020.0147

Article  CAS  PubMed  Google Scholar 

Chang E, Im D, Lee HY et al (2023) Impact of discontinuing isolation in a private room for patients infected or colonized with vancomycin-resistant enterococci (VRE) on the incidence of healthcare-associated VRE bacteraemia in a hospital with a predominantly shared-room setting. J Hosp Infect 132:1–7. https://doi.org/10.1016/j.jhin.2022.11.017

Article  CAS  PubMed  Google Scholar 

Freitas AR, Tedim AP, Francia MV et al (2016) Multilevel population genetic analysis of vanA and vanB Enterococcus faecium causing nosocomial outbreaks in 27 countries (1986–2012). J Antimicrob Chemother 71(12):3351–3366. https://doi.org/10.1093/jac/dkw312

Article  CAS  PubMed  Google Scholar 

Gao W, Howden BP, Stinear TP (2018) Evolution of virulence in Enterococcus faecium, a hospital-adapted opportunistic pathogen. Curr Opin Microbiol 41:76–82. https://doi.org/10.1016/j.mib.2017.11.030

Article  PubMed  Google Scholar 

Bender JK, Cattoir V, Hegstad K et al (2018) Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. Drug Resist Updat 40:25–39. https://doi.org/10.1016/j.drup.2018.10.002

Article  PubMed  Google Scholar 

Monticelli J, Knezevich A, Luzzati R, Di Bella S (2018) Clinical management of non-faecium non-faecalis vancomycin-resistant enterococci infection. Focus on Enterococcus gallinarum and Enterococcus casseliflavus/flavescens. J Infect Chemother 24:237–246. https://doi.org/10.1016/j.jiac.2018.01.001

Article  PubMed  Google Scholar 

Bonora MG, Solbiati M, Stepan E et al (2006) Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 44:1153–1155. https://doi.org/10.1128/JCM.44.3.1153-1155.2006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bi R, Qin T, Fan W, Ma P, Gu B (2018) The emerging problem of linezolid-resistant enterococci. J Glob Antimicrob Resist 13:11–19. https://doi.org/10.1016/j.jgar.2017.10.018

Article  PubMed  Google Scholar 

Holmberg SD, Solomon SL, Blake PA (1987) Health and economic impacts of antimicrobial resistance. Rev Infect Dis 9:1065–1078. https://doi.org/10.1093/clinids/9.6.1065

Article  CAS  PubMed  Google Scholar 

Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP (1996) Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 23:1234–1239. https://doi.org/10.1093/clinids/23.6.1234

Article  CAS  PubMed  Google Scholar 

Riccardi N, Antonello RM, Giacomelli A et al (2022) The challenge of infectious diseases consultations in the emergency department: an Italian nationwide survey. New Microbiol 45:260–268

PubMed  Google Scholar 

Chen H, Du Y, Xia Q, Li Y, Song S, Huang X (2020) Role of linezolid combination therapy for serious infections: review of the current evidence. Eur J Clin Microbiol Infect Dis 39:1043–1052. https://doi.org/10.1007/s10096-019-03801-x

Article  CAS  PubMed  Google Scholar 

Whang DW, Miller LG, Partain NM, McKinnell JA (2013) Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother 57:5013–5018. https://doi.org/10.1128/AAC.00714-13

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalil AC, Klompas M, Haynatzki G, Rupp ME (2013) Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 3:e003912. https://doi.org/10.1136/bmjopen-2013-003912

Article  PubMed  PubMed Central  Google Scholar 

Chiappini E, Conti C, Galli L, de Martino M (2010) Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 32:66–88. https://doi.org/10.1016/j.clinthera.2010.01.019

Article  CAS  PubMed  Google Scholar 

Garazzino S, Krzysztofiak A, Esposito S et al (2011) Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. J Antimicrob Chemother 66:2393–2397. https://doi.org/10.1093/jac/dkr285

Article  CAS  PubMed  Google Scholar 

Shi Y, Wu H-L, Wu Y-H et al (2023) Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis. World J Pediatr 19:129–138. https://doi.org/10.1007/s12519-022-00650-1

Article  CAS  PubMed  Google Scholar 

Riccardi N, Monticelli J, Antonello RM et al (2021) Therapeutic options for infections due to vanB genotype vancomycin-resistant enterococci. Microb Drug Resist 27:536–545. https://doi.org/10.1089/mdr.2020.0171

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

Article  PubMed  PubMed Central  Google Scholar 

Sweeney MT, Zurenko GE (2003) In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother 47:1902–1906. https://doi.org/10.1128/AAC.47.6.1902-1906.2003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campanile F, Bongiorno D, Mongelli G, Zanghì G, Stefani S (2019) Bactericidal activity of ceftobiprole combined with different antibiotics against selected Gram-positive isolates. Diagn Microbiol Infect Dis 93:77–81. https://doi.org/10.1016/j.diagnmicrobio.2018.07.015

Article  CAS  PubMed  Google Scholar 

Farina C, Russello G, Chinello P et al (2011) In vitro activity effects of twelve antibiotics alone and in association against twenty-seven Enterococcus faecalis strains isolated from Italian patients with infective endocarditis: high in vitro synergistic effect of the association ceftriaxone-fosfomycin. Chemotherapy 26(57):426–433. https://doi.org/10.1159/000330458

Article  CAS  Google Scholar 

Beitdaghar M, Ahmadrajabi R, Karmostaji A, Saffari F (2019) In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates. Wien Med Wochenschr 169:215–221. https://doi.org/10.1007/s10354-017-0603-1

Article  PubMed  Google Scholar 

Wareham DW, Abbas H, Karcher AM, Das SS (2006) Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect 52:300–304. https://doi.org/10.1016/j.jinf.2005.05.022

Article  CAS  PubMed  Google Scholar 

Ermertcan S, Hosgör-Limoncu M, Tasli H, Çilli F, Cosar G (2010) In vitro activity of linezolid in combination with vancomycin, teicoplanin, fusidic acid, and ciprofloxacin against gram-positive pathogens. Turkiye Klinikleri J Med Sci 30:59–64. https://doi.org/10.5336/medsci.2008-8693

Article  CAS  Google Scholar 

Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E (2019) In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci. J Antimicrob Chemother 74:1300–1305. https://doi.org/10.1093/jac/dkz010

Article  CAS  PubMed  Google Scholar 

Aligholi M, Emaneini M, Taherikalani M et al (2011) Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium. Acta Microbiol Immunol Hung 58:219–226. https://doi.org/10.1556/AMicr.58.2011.3.5

Article  CAS  PubMed  Google Scholar 

Luther MK, Arvanitis M, Mylonakis E, LaPlante KL (2014) Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. Antimicrob Agents Chemother 58:4612–4620. https://doi.org/10.1128/AAC.02790-13

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tong J, Jiang Y, Xu H et al (2021) In vitro antimicrobial activity of fosfomycin, rifampin, vancomycin, daptomycin alone and in combination against vancomycin-resistant enterococci. Drug Des Devel Ther 15:3049–3055. https://doi.org/10.2147/DDDT.S315061

Article  PubMed  PubMed Central  Google Scholar 

Descourouez JL, Jorgenson MR, Wergin JE, Rose WE (2013) Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother 57:1518–1520. https://doi.org/10.1128/AAC.02099-12

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi C, Xu S, Wu M et al (2019) pharmacodynamics of linezolid-plus-fosfomycin against vancomycin-susceptible and -resistant enterococci in vitro and in vivo of a Galleria mellonella larval infection model. Infect Drug Resist 12:3497–3505. https://doi.org/10.2147/IDR.S219117

Article  CAS